Business · 04/02/2019
FDA Clears Way for Pirfenidone Approval
The FDA has determined that ESBRIET (pirfenidone) film-coated tablets, 534 mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →